Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 4/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.40 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | TYK2 | P29597 | 3/20 | 0.39 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.39 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27316393 | 0.82 | TTK (0.46) | TTKCCNA2CDK2BRD4PDK2 | |
| SCHEMBL10094326 | 0.82 | BRD4 (0.50) | BRD4AXLPDK2IRAK1IRAK4 | |
| SCHEMBL19589893 | 0.81 | BRD4 (0.43) | BRD4AXLPDK2IRAK1IRAK4 | |
| SCHEMBL16962731 | 0.81 | TTK (0.46) | TTKCCNA2CDK2BRD4PDK2 | |
| SCHEMBL17806587 | 0.79 | PDK2 (0.44) | BRD4AXLPDK2IRAK1IRAK4 | |
| SCHEMBL24498531 | 0.79 | TTK (0.43) | TTKCCNA2CDK2BRD4PDK2 | |
| SCHEMBL15690351 | 0.79 | SMARCA2 (0.52) | TTKCCNA2CDK2BRD4PDK2 | |
| SCHEMBL20004004 | 0.79 | PDK2 (0.47) | TTKCCNA2CDK2BRD4PDK2 | |
| SCHEMBL18415016 | 0.77 | PDK2 (0.42) | TTKCCNA2CDK2BRD4PDK2 | |
| SCHEMBL17198730 | 0.77 | BRD4 (0.43) | TTKCCNA2CDK2BRD4PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023223055-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2023-11-23 | — | — | WO | disclosed |
| EP-4257587-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| WO-2022189810-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2022-09-15 | — | — | WO | disclosed |
| US-11021475-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200071315-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL-MYERS SQUIBB COMPANY | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021475-B2 | Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses | IFNG, IFNAR1, TYK2 | TTK 165/4885CCNA2 1143/4885CDK2 360/4885 |
| US-20200071315-A1 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | IFNG, IFNAR1, TYK2 | TTK 165/4885CCNA2 1143/4885CDK2 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.